Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story Anthony Mthembu | Photo Sonia Small
UFS students

The University of the Free State realises that the registration period can be stressful and frustrating to students for various reasons. 

In an effort to ensure that as many students as possible can successfully register for the 2022 academic year, the University of the Free State (UFS) has introduced a number of financial concessions. These financial concessions are specifically intended to fast-track the registration process of students who are currently awaiting confirmation of funding from the National Student Financial Aid Scheme (NSFAS).

Students with challenges regarding the application of the N+ rule

Students who have previously registered for foundation programmes and those who have continued with mainstream programmes will be allowed to register without the prerequisite of a first payment. This is on condition that they apply with the N+ rule (an added year of funding) and that their respective foundation programmes are included in the Department of Higher Education and Training (DHET)-funded list. Only students who do not have outstanding debt will qualify for this concession. 

2022 NSFAS-funded students

In addition, students whose funding has been confirmed by NSFAS for the 2022 academic year, will be permitted to register without a first payment.

Students without NSFAS 2022 funding confirmation with outstanding debt

Students awaiting NSFAS funding confirmation for 2022 will be allowed to register provisionally if their debt does not exceed R25 000.
Approval has been obtained to increase the maximum debt carried forward from 2021 from R20 000 to R25 000 to enable students to register provisionally.

Provisional registration for continuing NSFAS students 

Furthermore, continuing NSFAS students who are currently awaiting funding confirmation for the 2022 academic year, will be permitted to register provisionally. These are students
• who have been funded by NSFAS in 2021; 
• whose funding reflects on the NSFAS Bursary Agreement Report for the year 2021; and
• who have passed 50% of registered modules in 2021 or are in their final year in 2022. 
• The offer for continuing students to register provisionally also extend to those who are in the N+1 period. 

The official registration of these students will be subject to funding approval from NSFAS for the 2022 academic year. To ensure that all students are in classes on 21 February 2022, the abovementioned group of students have until 31 March 2022 to confirm their funding. 

Conditional registration for first-time entering students

With registration an overwhelming experience for first-time entering students, the UFS is also looking at concessions for these students who will start their studies at the university this year. 

The university has given first-time entering students who have applied for NSFAS funding and are awaiting confirmation, until 28 February 2022 to finalise their registration. 

Permission to finalise registration a week after the UFS registration cut-off time is granted to all South African first-time entering undergraduate students who are admitted and term-activated for 2022 NSFAS-funded academic programmes, and whose funding has not yet been confirmed. 

The amount payable for conditional registration for first-time entering students (residential and non-residential) is R500.

The UFS is hopeful that these financial concessions will assist in calming anxiety around the ongoing registration process.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept